objectives To evaluate the correlation of the total distance walked during the six-minute walk test (6MWT) with left ventricular function and quality of life in patients with Chagas Disease (ChD) complicated by heart failure.
Introduction
Chagas disease (ChD) is a neglected tropical disease caused by infection with Trypanosoma cruzi that still affects around 10 million people worldwide, mainly in Latin America [1] . However, migration from endemic countries to developed countries raises the need for surveillance and control in non-endemic areas. In the United States alone, 300 000 to 1 000 000 cases are believed to be present [2] . In Europe, ChD prevalence among Latin Americans migrants can be as high as 4.2% [3] .
Most patients are not identified during the acute phase of the disease and evolve into the chronic phase whose hallmark is the development of heart failure (HF) [4] . Nearly all patients are underprivileged and are followed at public outpatient clinics with limited resources to evaluate the severity of their HF [1] . One of the cardinal HF symptoms is fatigue; however, its subjective assessment may be challenging for the general physician and erroneous interpretations are possible. Furthermore, the gold standard test for evaluation of exercise tolerance, the cardiopulmonary exercise test, is rarely available at outpatient facilities. The six-minute walk test (6MWT) offers an objective assessment of the patient functional class. The 6MWT is a simple and cheap test that can be performed at any clinical facility without the need of any exercise equipment or advanced training for technicians [5] . The maximum distance walked in a period of 6 min is routinely used in several conditions, such as to evaluate functional impairment in HF [6, 7] , is a predictor of allcause mortality in HF [8] [9] [10] and presents a significant correlation with quality-of-life scores in HF [11] . Therefore, the 6MWT may be an important tool to objectively evaluate fatigue and dyspnoea symptoms reported by patients with ChD even in the most remote and underprivileged endemic areas.
We aimed to evaluate whether the total distance walked during the 6MWT would correlate with the severity of HF and quality of life in a group of patients with ChD complicated by HF.
Material and methods

Patients and study design
The study was approved by the local ethical committee under number 0034.0.009.000-11 and conformed with standards currently applied by the Brazilian National Committee for Research Ethics and with the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from all subjects following Good Clinical Practice.
Adult men and women with Chagas heart disease complicated with HF and followed at the outpatient service of the Evandro Chagas National Institute of Infectious Diseases (INI) of the Oswaldo Cruz Foundation were invited to participate in this cross-sectional study from February 2014 to November 2015. The INI is a public institution fully dedicated to clinical research in infectious diseases and is a national reference centre in the field of research and assistance for ChD.
Chagas disease was diagnosed by a positive result in two different serological tests using criteria previously published [12] . Heart failure was diagnosed based on Framingham criteria [13] . Chagas disease cardiac form was classified into stages following the current Brazilian Chagas disease consensus [14] : stage A (no HF symptoms with isolated changes in the electrocardiogram), stage B (no HF symptoms with segmental or global left ventricular [LV] systolic dysfunction), stage C (symptomatic HF) or stage D (end-stage HF). Information on comorbidities and medical treatment was based on the analysis of medical records. All patients underwent a medical consultation with their cardiologist on the day of the 6MWT to determine patients' functional class according to the New York Heart Association (NYHA) classification and to rule out any contraindication to the test. Patients with any of the following conditions were excluded from the study: unstable angina or acute myocardial infarction within the previous month, resting heart rate above 120 bpm, systolic blood pressure above 180 mmHg, diastolic blood pressure above 100 mmHg, difficulty walking, decompensated HF or patients who refused to collect blood sample for B-type natriuretic peptide (BNP) measurement. All patients performed 6MWT, collected blood for BNP measurement and answered quality-of-life questionnaires in the same day. Each patient performed only one 6MWT for this study.
6MWT
All tests were conducted by the same healthcare professionals with Basic Life Support training following international guidelines [15] . The test measures the distance that a patient can walk in a period of 6 min. Tests were performed along a flat, straight 10-m-long corridor with a hard surface. The starting line, which marked the beginning and the end of each 20-m lap, was marked on the floor using coloured tape. The length of the corridor was marked every 5 m, and the turnaround points were marked with an orange traffic cone. Heart rate, blood pressure, blood oxygen saturation and fatigue (modified Borg scale [16] ) were measured at baseline, at the end of the test and 5 min after the patient stopped walking. Patients were instructed to wear comfortable clothing and appropriate shoes for walking. Patients should not have exercised vigorously within 2 h of the beginning of the test. All patients rested for 10 min in a chair close to the start position before the test. Patients were instructed to walk the stipulated route, as much as they could, for 6 min. Test was performed close to the hospital environment allowing immediate clinical support and access to a crash cart. The test was immediately stopped if any of the following happened: chest pain, intolerable dyspnoea, leg cramps, staggering, dizziness, diaphoresis and pale or ashen appearance. Age-predicted maximal heart rate was calculated as follows: 208-0.7 9 age [17] . The predicted maximum walked distance value was calculated according to sex, age, weight and height [18] .
Quality-of-life questionnaire
Quality of life was evaluated using the 36-item shortform (SF-36) [19] and the Minnesota Living with HF Questionnaires (MLHFQ) [20] . The SF-36 is measured in eight scales: physical functioning, physical role functioning, bodily pain, general health perceptions, vitality, social role functioning, emotional role functioning and mental health. Item scores are scaled from 0 (worst health state) to 100 (best health state). The MLHFQ is used to evaluate the quality of life of patients with HF and includes 21 items related to psychological, physical and social impairments. The MLHFQ is assessed on a score from 0 (none) to 5 (very much) for each item, and the total MLHFQ score is obtained by adding the scores for all 21 items (range 0-105), where a worse quality of life is indicated by a higher score. BNP measurement B-type natriuretic peptide levels were measured using the BNP-32 enzyme immunoassay (EIA) kit (Peninsula Laboratories International; San Carlos, USA) according to the manufacturer's instructions (Protocol III). The measurable range of the BNP assay was from 0.02 to 1000 pg/ml.
Echocardiography
Echocardiograms were performed using phased-array ultrasound system (Vivid 7, GE Medical Systems, Milwaukee, WI, USA) equipped with M4S phased-array transducer within 3 months of day the 6MWT was performed. Cardiac dimensions and Doppler measurements were obtained as previously described [21] . M-mode echocardiography was used to measure left atrial diameter, and LV end-diastolic and end-systolic diameters. LV ejection fraction was determined by modified Simpson's rule with images obtained from apical four-and twochamber views. Pulsed-wave Doppler was obtained in apical four-chamber view. From transmitral recordings, the peak early (E) and late (A) diastolic filling velocities and E/A ratio were obtained. Peak early (E') and late (A') diastolic myocardial velocities are averages of the values obtained by spectral pulsed-wave tissue Doppler of the mitral annulus at the septal and lateral positions. LV diastolic function was evaluated as recommended [22] and classified as normal, diastolic dysfunction grade I to III or non-classifiable. Pulmonary artery systolic pressure (PASP) was derived from continuous-wave Doppler interrogation of tricuspid regurgitation. Mitral regurgitation degree was classified as mild to severe following international guideline [23] . RV systolic function was evaluated by measuring the peak systolic myocardial velocity (RV S') of the lateral tricuspid annulus, and the tricuspid annular plane excursion (TAPSE), as recommended [24] .
Statistical analysis
Statistical analysis was performed using Statistical Package for the Social Sciences software (SPSS Inc., Chicago, IL) version 16.0. All continuous variables were tested for normality (Kolmogorov-Smirnov test). Continuous data are presented as mean AE SD or median with 25-75th interquartile range (IQR), as appropriate. Frequency data are presented as numbers and percentages. Correlation between studied variables was tested by Pearson or Spearman correlation coefficients, as appropriate. BNP serum levels had a skewed distribution, and log transformation was applied before correlation analysis. The strength of the studied correlations was classified as previously described [25] . Data between groups were compared using ANOVA followed by Bonferroni post hoc analysis. Outcomes were considered significant when P < 0.05.
Results
A total of 53 patients were invited to participate in this study. From those, 13 subjects did not perform the 6MWT due to decompensated HF (n = 3), difficulty walking (n = 7), cerebral aneurysm (n = 1) or refusal to collect blood sample for BNP measurement (n = 2) and were excluded from the study. Forty patients with Chagas heart disease complicated with HF were evaluated (19 male; 60 AE 12 years old). Most patients presented NYHA functional class II and the stage C of the cardiac form. Patients received optimal medical therapy for HF according to international HF guidelines [26] (Table 1) . Most patients presented LV ejection fraction below 35% and diastolic dysfunction grade I. Diastolic dysfunction was not classified in eleven patients: seven due to atrial fibrillation and four patients due to severe mitral regurgitation. About one-third of the patients presented RV systolic dysfunction (Table 2) . Only two of 40 subjects (5%) ceased walking before 6 min had elapsed and failed to resume walking, one due to dizziness and other due to extreme fatigue. No patient presented cardiovascular adverse events during the test or its recovery phase. Thus, 38 subjects had full 6MWT and BNP data sets for analysis. The average distance covered was 337 AE 105 m, which corresponded to 70.3 AE 17.4% of the predicted maximum walked distance value. Heart rate increased 41% at the end of the 6MWT and recovered towards baseline 5 min after the 6MWT. The heart rate at the end of the 6MWT corresponded to 54.9 AE 11.2% of the age-predicted maximal heart rate. Systolic and diastolic blood pressure increased by 16% and 17%, respectively, at the end of the 6MWT and recovered towards baseline 5 min after the 6MWT. Oxygen saturation level did not change significantly during the 6MWT. Fatigue perception increased 100% during the 6MWT (Table 3 ).
The patients who failed to complete the 6MWT due to fatigue or dizziness had BNP serum levels of 480 pg/ml and 990 pg/ml, respectively. For correlation analysis, we only considered the data of the 38 patients who completed the 6MWT. BNP serum levels had a skewed distribution that changed to normal after logarithmic transformation, which allowed the use of parametric test for correlation studies. The distance covered during the 6MWT presented a fair but significant negative correlation with BNP serum levels after logarithmic transformation (r = À0.37; P = 0.02; Figure 1 ; Table 4 ). However, there was no significant association between the distance covered during the 6MWT and the functional class or age ( Table 4 ). The distance covered during the 6MWT also presented a fair negative correlation with the peak early wave diastolic filling velocity, the E/E' ratio, the degree of LV diastolic dysfunction and moderate negative correlation with mitral regurgitation and PASP (Table 4) .
Quality of life evaluated at the same day of the 6MWT was available for 32 patients. The distance covered during the 6MWT presented a moderate negative correlation with the MLHFQ and positive correlation with several domains of the SF-36 quality-of-life scores. The strength of the correlations between the distance covered during the 6MWT and SF-36 domains ranged from moderate (physical functioning and bodily pain) to fair (physical role functioning) ( Table 4) .
Discussion
The 6MWT is a handy, simple and safe test that can be extremely useful to evaluate ChD patients with HF, as it has a significant correlation with objective measures of exercise capacity [8, 27, 28] and prognostic value in HF [7] [8] [9] . In this study, we demonstrated that 6MWT could be safely performed in ChD patients with HF and that the distance covered during 6MWT was associated with echocardiographic parameters, quality-of-life scores and BNP. Thus, we propose this method to be used to evaluate fatigue and dyspnoea symptoms and functional class in outpatients with ChD and HF with the purpose to help the identification of patients needing referral to tertiary centres for further evaluation and treatment optimisation.
The 6MWT was safely performed in patients with ChD complicated with HF as none of the patients presented major cardiac events during or immediately after the test. Furthermore, the test was feasible and well accepted as only two patients interrupted the test. In addition, the distance covered was similar to other studies that evaluated 6MWT in HF [29] [30] [31] [32] and in ChD with HF [33] . The average distance covered during the 6MWT correlated with BNP, echocardiographic parameters and quality-of-life scores. BNP is released by ventricular cardiomyocytes under high pressure and volume overload states and is elevated and predict prognosis in HF [34] and ChD [35] . In our study and in other [36] , BNP presented a fair but significant negative correlation with the distance covered during the 6MWT, as patients with higher LV filling pressure are expected to have a lower tolerance to exercise. On the other hand, others found no correlation between BNP [37] or pulmonary wedge pressure [8, 28] and the distance covered during the 6MWT in patients with HF secondary to other aetiologies. The absence of a strong correlation between BNP and the distance covered during the 6MWT may be due to the influence of several factors on BNP and 6MWT results. BNP serum levels depend not only on LV filling pressure but also on age, sex, associated comorbidities and obesity [34, 38] , while 6MWT in HF is affected not only by HF severity, but also by age, weight, height, sex, impaired cognition, comorbidities (vision, pulmonary disease, stroke, musculoskeletal disorders), motivation, medication, variation in test protocol and familiarity with the 6MWT protocol [39] . The distance covered during the 6MWT in our study had no correlation with LV ejection fraction or diameters, as shown by others in patients with HF [6, 8, 28, 37] . Another study with patients with ChD showed a weak but significant correlation between LV ejection fraction and the distance covered during the 6MWT [36] . However, there was a significant correlation with LV diastolic function, PASP and mitral regurgitation degree. We attribute this finding to the fact that these parameters are associated with higher LV filling pressure and, therefore, intolerance to exercise [22, 23] . The 6MWT objectively evaluates patients' functional class which depends more on the hemodynamic status than on LV ejection fraction.
Our results also showed correlation between 6MWT and quality-of-life scores. The distance covered during the 6MWT presented a moderate positive correlation with several domains of the SF-36 and a moderate negative correlation with the MLHFQ quality-of-life scores. Others [11, 37] also found a correlation between 6MWT results and quality-of-life scores in patients with HF and correlation between the MLHFQ and 6MWT in patients with ChD and HF [33] .
Importantly, the distance covered during the 6MWT is a mortality (all-cause or cardiac) and worsening HF predictor in subjects with HF [8] [9] [10] 40] but not independent from cardiopulmonary exercise test parameters [28, 41] . The fact that 6MWT is not an independent predictor when peak oxygen uptake is included in multivariate analysis [28, 41] is probably due to their significant correlation [7, 26, 27] In fact, in patients with Chagas heart disease, a recent study found significant correlation between the distance covered at 6MWT and the predicted peak oxygen uptake [42] . Therefore, both tests (6MWT and cardiopulmonary exercise test) may give similar prognostic value and therefore reinforces the importance of 6MWT in underprivileged areas where cardiopulmonary exercise test is rarely available.
Strengths, clinical implication and limitations
This is the first study to correlate 6MWT with LV diastolic and systolic function, BNP, and quality of life in a population of ChD patients complicated by HF. We were able to demonstrate the safety and feasibility of the test in this population and the correlation with echocardiographic parameters, BNP and quality of life. LV diastolic function [43] and BNP [35] predict cardiac events in ChD, and quality of life is at the same time an important goal of HF treatment and a mortality predictor in HF [11] . Therefore, the correlations of these parameters with 6MWT in ChD point out the important clinical application of this examination in this population. Moreover, others [42] demonstrated the correlation between the distance covered at 6MWT and predicted peak oxygen uptake in ChD. Together with the fact that the 6MWT is simple to perform and easy to interpret, 6MWT becomes a test that can be adopted in endemic areas to evaluate patients with ChD, as also recommended for patients with HF [39] .
Our results are limited by the fact that we performed a single 6MWT for each patient. Therefore, we did not study the reproducibility of our results. However, the high reproducibility of the 6MWT was previously described by others who found intraclass correlation ranging from 0.91 [44] to 0.96 [8] . We could not rule out a learning effect on our results as each patient performed a single 6MWT. However, minimal differences in 6MWT distances over time are reported in patients with stable HF [45] . Moreover, when two 6MWT were obtained one month apart, the baseline distance predicted mortality and hospitalisation while the change in distance walked from baseline to 1 month did not predict any end point [10] . In fact, a recent guideline [46] suggests that learning effect is clinical important when 6MWT is used to evaluate response to treatment or change over time, which were not the objective of our study, while the learning effect is less important when the objective is to stage disease or assess risk and one test may suffice.
Another potential limitation of our study is the 10-m course length used in contrast to the 30-m course length recommended by guidelines [15, 46] . This may result in a decrease in the distance covered by the patient during the 6MWT in our study, as demonstrated for patients with chronic obstructive pulmonary disease [47] . However, several other studies on HF have used course lengths similar to ours [30, 31] and the distance covered in our study is similar to that found in other studies on HF [29] [30] [31] [32] and in ChD with HF [33] . In fact, many other factors may influence the 6MWT result for a specific subject [39] and physicians should bear that in mind when interpreting the result of a specific patient or comparing studies.
Conclusion
The distance walked during the 6MWT correlates with BNP, quality of life and parameters of LV diastolic function in ChD patients with HF. We propose this test to be adopted in endemic areas with limited resources to aid in the identification of patients who need referral to tertiary centres for further evaluation and treatment.
